CRN posts letter to the editor that JAMA declined to publish
WASHINGTON — The Council for Responsible Nutrition on Tuesday posted a letter to the editor challenging an article critical of dietary supplements that was published July 5 and in the July 27 issue of the Journal of the American Medical Association.
JAMA had declined to publish the letter, CRN reported.
"In his July 5 article about regulatory and public health issues relating to dietary supplements, communications professor Bryan Denham offers up an inaccurate history of dietary supplement regulation, which unfortunately readers may accept at face value," opened Annette Dickinson, former president and current consultant for CRN. "This short letter will address only a few of the more egregious factual errors."
In the letter, Dickinson challenges several statements regarding the history of dietary supplement regulation. "Denham is entitled to his own opinion about dietary supplements, but he is not entitled to his own version of the facts," Dickinson concluded. "He calls for a more sophisticated discussion of the regulatory issues and public health concerns relating to dietary supplements, but his article fails to contribute to that end."
For a full account of the letter and the factors that led up to CRN’s posting of the letter online, click here.
Mike Bloom resigns from CVS/pharmacy, assumes president, COO role at Family Dollar
NEW YORK — Longtime CVS/pharmacy executive Mike Bloom has resigned from the company and will serve as president and COO of Family Dollar Stores.
“Mike Bloom, EVP of merchandising and supply chain, has resigned from the company. We thank him for his many contributions to the success of our retail business over the past 19 years and wish him luck in his future endeavors,” stated Carolyn Castel, VP of corporate communications at CVS Caremark, in a statement sent to Drug Store News.
Ron Link, SVP of logistics, and Richard Widdowson, VP of inventory replenishment, will report to Scott Baker, EVP of operations, real estate and supply chain. Judy Sansone, VPMM, will assume responsibility for the merchandising organization at CVS/pharmacy.
In addition to hiring Bloom, Family Dollar Stores, which operates more than 7,000 stores across 44 states, has promoted Dorlisa Flur as vice chair, strategy and chief administrative officer. Both Bloom and Flur will report to Howard Levine, chairman and CEO.
Flur joined Family Dollar in 2004 as SVP of strategy and business development. In October 2008, Flur was promoted to EVP of strategy and marketing, and in August 2009 was promoted to EVP and chief merchandising officer.
The appointments follow the announced retirement of R. James Kelly as Family Dollar’s president and COO after 15 years with the company. Kelly will serve as vice chair over the next six months, working closely with Bloom and Flur to assist in the transition.
In March 2010, Bloom was promoted to EVP merchandising and supply chain for CVS/pharmacy, leading an integrated end-to-end network, managing store layout as well as the selection, purchasing, inventory and supply of product to CVS stores. Bloom joined CVS as part of the People’s Drug Store acquisition in 1991. He served as VPMM for consumer health care and later led the Life store prototype initiative. He was promoted to SVP merchandising in 2003 and SVP of merchandising and supply chain in 2009.
Study: Lilly drug keeps common lung cancer under control in elderly patients
INDIANAPOLIS — A drug made by Eli Lilly prevented the most common form of lung cancer from progressing in elderly patients when added to chemotherapy, according to results of a late-stage clinical trial.
Lilly released results of the 939-patient phase-3 "PARAMOUNT" study, which found that maintenance therapy with the injected drug Alimta (pemetrexed), added to the chemotherapy drug cisplatin, reduced the risk of disease progression in patients ages 70 years and older with advanced nonsquamous no-small cell lung cancer, or NSCLC.
In the study, patients were given Alimta or a placebo. Among the 92 patients ages 70 years and older, Alimta reduced the risk of disease progression by 65% compared with placebo. Among those younger than 70 years, the drug reduced disease progression by 31%.
Results from the analysis were presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm.